Potential

Zacks Small Cap Research – LGMK: Potential Revenue Catalysts: GSA Approval, Medicaid Waivers, Device Upgrades – Go Health Pro

by
Zacks Small Cap Research – LGMK: Potential Revenue Catalysts: GSA Approval, Medicaid Waivers, Device Upgrades – Go Health Pro

By M. Marin NASDAQ:LGMK READ THE FULL LGMK RESEARCH REPORT Recent introduction of next-gen Guardian Alert 911 Plus in 1Q25… LogicMark, Inc. (NASDAQ:LGMK) launched the next generation of the Guardian Alert 911 Plus in February 2025. The next-generation Guardian Alert 911 Plus expands the company’s product suite and offers an upgrade from the earlier version … Read more

China’s narrowing tech gap with US creates investment potential: global fund managers – Go Health Pro

by
China’s narrowing tech gap with US creates investment potential: global fund managers – Go Health Pro

China’s emergence as a leader in renewable energy, electric vehicles and artificial intelligence (AI) will provide long-term investment opportunities for international investors, according to business leaders. “For a long time, China was viewed as a copycat,” Fred Hu Zuliu, chairman and CEO of Primavera Capital, said during panel discussion at the first World Economic Forum … Read more

Unlock the potential of Microsoft Teams – Go Health Pro

by
Unlock the potential of Microsoft Teams – Go Health Pro

At Neuways, we believe technology should simplify your work, not add complexity. That’s why we provide expert managed IT support to help businesses make the most of powerful productivity tools like Microsoft Teams. Microsoft Teams is more than just a chat app—it’s a full collaboration platform with ever-evolving features designed to help your team work … Read more

Zacks Small Cap Research – MGRM: Monogram’s Potential for 2025 Commercialization of its mBôs Total Knee Arthroplasty Robotic System Supports Price Target of $6.00. – Go Health Pro

by

By Thomas Kerr, CFA NASDAQ:MGRM READ THE FULL MGRM RESEARCH REPORT Regulatory Update On February 26, 2025, Monogram (NASDAQ:MGRM) announced an update regarding its 510(k) premarket filing submission to the FDA for the company’s mBôs TKA System. The company stated it had completed all supplemental testing and submitted its formal response to the Additional Information … Read more

Zacks Small Cap Research – SNGX: Presentation Highlights HyBryte Potential in CTCL… – Go Health Pro

by
Zacks Small Cap Research – SNGX: Presentation Highlights HyBryte Potential in CTCL… – Go Health Pro

By David Bautz, PhD NASDAQ:SNGX READ THE FULL SNGX RESEARCH REPORT Business Update Presentation Highlights HyBryte Potential in CTCL In January 2025, Dr. Neal Bhatia presented at two dermatology conferences on “Off-Label Uses of PDT” (photodynamic therapy). Dr. Bhatia is the Director of Clinical Dermatology at Therapeutics Clinical Research, a member of Soligenix’s (NASDAQ:SNGX) scientific … Read more